News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Suven Life Sciences Ltd Secures 7 Product Patents for Their Nces in Several Key Markets in the World

4/26/2011 10:25:17 AM

HYDERABAD, INDIA (Apr 26, 2011) – Suven Life Sciences Ltd (Suven) announces today that the grant of seven (7) product patents, two from Canada (CA 2,618,636 & CA 2,626,646), three from India (243298, 244912, 246200), one from Eurasia (14694) and one from Japan (4571507) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2023,2024 and 2025.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

With these new patents, Suven has a total of five(5) granted patents from Canada, thirteen(13) granted patents from India, nine (9) granted patents from Eurasia and four (4) granted from Japan for the NCEs. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $30 billion market potential globally” says Venkat Jasti, CEO of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. The Company has twelve (12) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

For more information on Suven please visit our Web site at

Read at

comments powered by Disqus